Mary Ann Anderson, MBBS, PhD, Talks Emerging BCL2 Inhibitors in CLL at SOHO 2023
What is a BCL 2 inhibitor and when is it used? #AMLПодробнее
Anderson MA (2013): Targeting Bcl-2 in the treatment of leukemia and lymphomaПодробнее
Drs. Naval Daver, Rami Komrokji Visit The HemOnc Pulse at SOHO 2023Подробнее
World CLL Day with Dr. AndersonПодробнее
TRANSCEND-CLL-004 study update: safety and efficacy of liso-cel in R/R CLLПодробнее
Talking chronic lymphocytic leukaemia (CLL) with Dr Mary Ann AndersonПодробнее
Factors to consider when selecting initial therapy in CLL: patient features & preferenceПодробнее
Advances in non-covalent BTK inhibitors for CLL: BRUIN study updateПодробнее
BCL-2 Inhibitors Selectively Eliminate Senescent Cells | Aging-USПодробнее
Agnesian HealthCare: Christine's StoryПодробнее
MEDTalk 2022: "Immunotherapy: Empowering the Immune System to Besiege Cancers”Подробнее
SA Vaccinology Update: Prof Annette Braunack MayerПодробнее
Clinical ControversiesПодробнее
Keynote Lecture: Targeted Therapies in Lung Cancer 2.0 – Advances and PromisesПодробнее
Dr. Jay AndersenПодробнее
The IBIS-I Breast Cancer Clinical Trial - Breast Cancer TrialsПодробнее
Myeloma highlights from SOHO 2023: updates with the use of novel targeted immunotherapiesПодробнее
